id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-D-1848-0023,FDA,FDA-2023-D-1848,Stimulant Use Disorders: Developing Drugs for Treatment; Guidance for Industry; Draft Guidance,Other,Guidance,2026-05-13T04:00:00Z,2026,5,2026-05-13T04:00:00Z,,2026-05-13T15:18:07Z,,1,0,09000064b92d0c8f
FDA-2023-D-1848-0002,FDA,FDA-2023-D-1848,"Stimulant Use Disorders: Developing Drugs for Treatment Guidance for Industry
DRAFT GUIDANCE",Other,Guidance,2023-10-05T04:00:00Z,2023,10,2023-10-05T04:00:00Z,2023-12-05T04:59:59Z,2024-11-07T00:54:06Z,,1,0,09000064860488a7
FDA-2023-D-1848-0001,FDA,FDA-2023-D-1848,Stimulant Use Disorders: Developing Drugs for Treatment; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-10-05T04:00:00Z,2023,10,,,2023-10-05T14:22:20Z,2023-22189,0,0,09000064860474b2